Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TYRA
Upturn stock ratingUpturn stock rating

Tyra Biosciences Inc (TYRA)

Upturn stock ratingUpturn stock rating
$10.7
Last Close (24-hour delay)
Profit since last BUY-2.01%
upturn advisory
Consider higher Upturn Star rating
BUY since 22 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TYRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $30.14

1 Year Target Price $30.14

Analysts Price Target For last 52 week
$30.14 Target price
52w Low $6.42
Current$10.7
52w High $29.6

Analysis of Past Performance

Type Stock
Historic Profit -70.58%
Avg. Invested days 19
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 569.00M USD
Price to earnings Ratio -
1Y Target Price 30.14
Price to earnings Ratio -
1Y Target Price 30.14
Volume (30-day avg) 8
Beta 1.08
52 Weeks Range 6.42 - 29.60
Updated Date 08/15/2025
52 Weeks Range 6.42 - 29.60
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.63

Earnings Date

Report Date 2025-08-14
When -
Estimate -0.53
Actual -0.47

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -19%
Return on Equity (TTM) -27.04%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 256183493
Price to Sales(TTM) -
Enterprise Value 256183493
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -6.95
Shares Outstanding 53178000
Shares Floating 14570237
Shares Outstanding 53178000
Shares Floating 14570237
Percent Insiders 3.69
Percent Institutions 110.41

ai summary icon Upturn AI SWOT

Tyra Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Tyra Biosciences, Inc. is a precision oncology company focused on developing next-generation therapies to overcome tumor resistance and improve outcomes for cancer patients. Founded in 2018, they leverage their SNAP platform to design selective therapies. They went public in 2020.

business area logo Core Business Areas

  • Precision Oncology Drug Development: Developing small molecule drugs targeting cancer drivers and resistance mechanisms.
  • SNAP Platform: Utilizing their SNAP platform to rapidly and precisely design novel cancer therapies.

leadership logo Leadership and Structure

The leadership team includes Todd Harris (CEO). The company is structured with research, development, and clinical operations divisions.

Top Products and Market Share

overview logo Key Offerings

  • TYRA-300 (pan-FGFR inhibitor): An investigational pan-FGFR inhibitor designed to address acquired resistance mutations in FGFR-altered cancers. Currently in clinical trials. No market share data available as it is pre-commercial. Competitors include existing FGFR inhibitors and other companies developing similar therapies.
  • TYRA-200 (RET inhibitor): An investigational RET inhibitor that addresses selectivity and overcomes clinical resistance. Currently in clinical trials. No market share data available as it is pre-commercial. Competitors include Eli Lilly's Retevmo (selpercatinib) and Blueprint Medicines' Gavreto (pralsetinib).

Market Dynamics

industry overview logo Industry Overview

The oncology drug market is a large and rapidly growing market driven by increasing cancer incidence and advances in treatment options, particularly precision oncology.

Positioning

Tyra is positioned as a precision oncology company focused on overcoming drug resistance with its SNAP platform, which could provide a competitive advantage over companies developing less selective or less adaptable therapies.

Total Addressable Market (TAM)

The TAM for cancer therapies is estimated to be hundreds of billions of dollars. Tyra is positioned to capture a portion of this TAM with its pipeline of targeted therapies addressing specific resistance mechanisms.

Upturn SWOT Analysis

Strengths

  • SNAP platform technology
  • Focus on drug resistance
  • Experienced leadership team
  • Strong intellectual property portfolio
  • Targeted pipeline

Weaknesses

  • Early-stage clinical pipeline
  • Dependence on clinical trial success
  • Limited commercialization experience
  • High cash burn rate

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of SNAP platform to other therapeutic areas
  • Positive clinical trial results
  • FDA approval and commercialization of lead candidates

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • BMY
  • ROG.SW

Competitive Landscape

Tyra differentiates itself through its SNAP platform. Success depends on clinical data compared to the above competitor's already FDA approved products.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited as the company is still in the early stages of development.

Future Projections: Future growth is dependent on clinical trial success and eventual commercialization of its pipeline candidates.

Recent Initiatives: Focus on advancing TYRA-300 and TYRA-200 through clinical trials, expanding SNAP platform capabilities.

Summary

Tyra Biosciences is an early-stage precision oncology company with a promising SNAP platform and targeted pipeline. Its success heavily relies on the outcome of ongoing clinical trials. While the SNAP platform provides a competitive edge, the company faces challenges typical of biotech startups, including high cash burn and clinical development risks. Investors should monitor clinical data and partnerships closely.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Tyra Biosciences Inc. investor relations website
  • SEC filings
  • Analyst reports
  • Company press releases

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tyra Biosciences Inc

Exchange NASDAQ
Headquaters Carlsbad, CA, United States
IPO Launch date 2021-09-15
Co-Founder, President, CEO, Secretary, Treasurer & Director Dr. Todd Harris Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 60
Full time employees 60

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.